secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2021-12-27T23:59:59+00:00
Accession:  0001564590-21-061212
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics resubmits Tyvaso DPI NDA to FDA after CRL
-------------------------------------------------------------

- UT received a Complete Response Letter from FDA on Oct 18, 2021 for Tyvaso DPI.
- UT disclosed on Dec 27, 2021 that it has resubmitted the NDA to FDA.
- Tyvaso DPI uses MannKind's Inhalation technology; resubmission is a key regulatory milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000156459021061212/0001564590-21-061212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000156459021061212/mnkd-8k_20211227.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-061212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer